Notch3 acetylation/deacetylation represents a key regulatory switch in the control of Notch signaling, and represents a suitable drug target for Notch3-sustained T-cell acute lymphoblastic leukemia therapy [13]. Here, NOTCH3 is linked to T-cell acute lymphoblastic leukemia.